Kardioglykosidy: terapeutický potenciál pro léčbu nádorových onemocnění

  • J. Bejček Ústav biochemie a mikrobiologie, Vysoká škola chemicko-technologická v Praze, Praha
  • W. Spiwok Ústav biochemie a mikrobiologie, Vysoká škola chemicko-technologická v Praze, Praha http://orcid.org/0000-0001-8108-2033
  • E. Kmoníčková Ústav farmakologie a toxikologie, Lékařská fakulta v Plzni, Univerzita Karlova, Plzeň http://orcid.org/0000-0002-0940-4605
  • T. Ruml Ústav biochemie a mikrobiologie, Vysoká škola chemicko-technologická v Praze, Praha http://orcid.org/0000-0002-5698-4366
  • S. Rimpelová Ústav biochemie a mikrobiologie, Vysoká škola chemicko-technologická v Praze, Praha http://orcid.org/0000-0002-3008-1396
Klíčová slova: digoxin, digitoxin, kardioglykosidy (srdeční glykosidy), ouabain, protinádorová aktivita, přírodní látky, sodno-draselná pumpa (Na⁺/K⁺-ATPasa)

Abstrakt

Cardiac glycosides are bioactive natural compounds well-known mainly for their potency to induce a cardiotonic effect by sodium-potassium ATPase inhibition. For many years, cardiac glycosides have been utilized to treat heart failure and arrhythmias; however, according to novel research studies, these compounds have an enormous potential also as medicinally promising compounds for cancer treatment. The goal of this review is to provide a brief insight into the research topic of cardiac glycosides by describing their chemical structure, biosynthesis, the mechanism of action, anticancer potential alongside with the most significant clinical trials, as well as their other biological activities, such as the modulation of the immune system.

Publikované
2021-01-15
Sekce
Články